CYTK Cytokinetics Inc

$38.34

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Cytokinetics Inc

Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.

Website: https://www.cytokinetics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1061983
Address
280 EAST GRAND AVENUE, ., SOUTH SAN FRANCISCO, CA, US
Valuation
Market Cap
$4.71B
P/E Ratio
nan
PEG Ratio
-0.42
Price to Book
60.31
Performance
EPS
$-5.26
Dividend Yield
—
Profit Margin
0.00%
ROE
-572.00%
Technicals
50D MA
$42.94
200D MA
$50.45
52W High
$68.76
52W Low
$32.74
Fundamentals
Shares Outstanding
119M
Target Price
$78.30
Beta
0.94

CYTK EPS Estimates vs Actual

● Estimated
● Actual

CYTK News & Sentiment

Aug 20, 2025 • GlobeNewswire NEUTRAL
Cytokinetics Names Jim Daly to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with ...
Aug 20, 2025 • Benzinga NEUTRAL
Cytokinetics Names Jim Daly to Board of Directors - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025.
Aug 20, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ...
Aug 20, 2025 • Benzinga SOMEWHAT-BULLISH
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer - Rezolute ( NASDAQ:RZLT )
REDWOOD CITY, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Rezolute, Inc. RZLT ( "Rezolute" or the "Company" ) , a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism ( HI ) , today announced the appointment of Sunil Karnawat as Chief Commercial Officer, ...
Aug 19, 2025 • Benzinga NEUTRAL
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 105,169 shares of common stock and 70,879 restricted stock units ( RSUs ) that will be settled in shares ...
Aug 11, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Sentiment Snapshot

Average Sentiment Score:

0.058
50 articles with scored sentiment

Overall Sentiment:

Neutral

CYTK Reported Earnings

Feb 25, 2025
Dec 31, 2024 (Post market)
-0.09 Surprise
  • Reported EPS: $-1.26
  • Estimate: $-1.17
  • Whisper: —
  • Surprise %: -7.3%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.11 Surprise
  • Reported EPS: $-1.36
  • Estimate: $-1.25
  • Whisper: —
  • Surprise %: -8.8%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.25 Surprise
  • Reported EPS: $-1.31
  • Estimate: $-1.06
  • Whisper: —
  • Surprise %: -23.6%
May 08, 2024
Mar 31, 2024 (Post market)
-0.19 Surprise
  • Reported EPS: $-1.33
  • Estimate: $-1.14
  • Whisper: —
  • Surprise %: -16.7%
Feb 27, 2024
Dec 31, 2023 (Post market)
-0.41 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-0.97
  • Whisper: —
  • Surprise %: -42.3%
Nov 02, 2023
Sep 30, 2023 (Post market)
-0.61 Surprise
  • Reported EPS: $-1.35
  • Estimate: $-0.74
  • Whisper: —
  • Surprise %: -82.4%
Aug 03, 2023
Jun 30, 2023 (Post market)
-0.19 Surprise
  • Reported EPS: $-1.34
  • Estimate: $-1.15
  • Whisper: —
  • Surprise %: -16.5%
May 04, 2023
Mar 31, 2023 (Post market)
-0.18 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-1.20
  • Whisper: —
  • Surprise %: -15.0%
Mar 01, 2023
Dec 31, 2022 (Post market)
-0.24 Surprise
  • Reported EPS: $-1.45
  • Estimate: $-1.21
  • Whisper: —
  • Surprise %: -19.8%

Financials